Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 5
1986 5
1987 9
1988 4
1989 1
1990 3
1991 2
1992 5
1993 6
1994 9
1995 6
1996 13
1997 20
1998 14
1999 16
2000 27
2001 31
2002 46
2003 38
2004 65
2005 67
2006 81
2007 100
2008 96
2009 110
2010 110
2011 112
2012 107
2013 97
2014 95
2015 101
2016 81
2017 57
2018 70
2019 68
2020 65
2021 65
2022 46
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

1,597 results
Results by year
Filters applied: . Clear all
Page 1
Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Carhart-Harris R, et al. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. N Engl J Med. 2021. PMID: 33852780 Clinical Trial.
RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. ...Other secondary outcomes …
RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean sc …
Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP. Strawn JR, et al. J Clin Psychiatry. 2020 Aug 25;81(5):20m13396. doi: 10.4088/JCP.20m13396. J Clin Psychiatry. 2020. PMID: 32857933 Free PMC article. Clinical Trial.
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: Escitalopram reduces anxiety symptoms, and pharmacogenetics variables influence the trajectory and magnitude of improvement. Variation …
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: …
Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial.
Blumenthal JA, Smith PJ, Jiang W, Hinderliter A, Watkins LL, Hoffman BM, Kraus WE, Liao L, Davidson J, Sherwood A. Blumenthal JA, et al. JAMA Psychiatry. 2021 Nov 1;78(11):1270-1278. doi: 10.1001/jamapsychiatry.2021.2236. JAMA Psychiatry. 2021. PMID: 34406354 Free PMC article. Clinical Trial.
The mean (SD) age was 64.6 (9.6) years, and 37 participants (29%) were women. Participants randomized to the exercise group and escitalopram group reported greater reductions in HADS-A (exercise, -4.0; 95% CI, -4.7 to -3.2; escitalopram, -5.7; 95% CI, -6.4 to -5.0) …
The mean (SD) age was 64.6 (9.6) years, and 37 participants (29%) were women. Participants randomized to the exercise group and escitalop …
Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial.
Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. Hoge EA, et al. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi: 10.1001/jamapsychiatry.2022.3679. JAMA Psychiatry. 2023. PMID: 36350591 Clinical Trial.
Baseline mean (SD) CGI-S score was 4.44 (0.79) for the MBSR group and 4.51 (0.78) for the escitalopram group in the per-protocol sample and 4.49 (0.77) vs 4.54 (0.83), respectively, in the randomized sample. At end point, the mean (SD) CGI-S score was reduced …
Baseline mean (SD) CGI-S score was 4.44 (0.79) for the MBSR group and 4.51 (0.78) for the escitalopram group in the per-protoc …
[Psilocybin compared with escitalopram for depression].
Strous JFM. Strous JFM. Ned Tijdschr Geneeskd. 2022 Jan 17;166:D6318. Ned Tijdschr Geneeskd. 2022. PMID: 35138714 Clinical Trial. Dutch.
Carhart-Harris et al. performed a study in which they compared psilocybin in combination with psychotherapy to escitalopram in combination with psychotherapy for depression. In this commentary, the author first summarizes the study results: in this double blind randomized …
Carhart-Harris et al. performed a study in which they compared psilocybin in combination with psychotherapy to escitalopram in combin …
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME. Becker AM, et al. Clin Pharmacol Ther. 2022 Apr;111(4):886-895. doi: 10.1002/cpt.2487. Epub 2021 Nov 22. Clin Pharmacol Ther. 2022. PMID: 34743319 Free PMC article. Clinical Trial.
Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin administration, or 14 days of placebo pretreatment before psilocybin administration. ...Escitalopram did not alter HTR2A or SCL6A4 gene …
Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin ad …
Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression.
Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP, Nogueira BS, Aparicio LVM, Razza LB, Chamorro R, Tort LC, Fraguas R, Lotufo PA, Gattaz WF, Fregni F, Benseñor IM; ELECT-TDCS Investigators. Brunoni AR, et al. N Engl J Med. 2017 Jun 29;376(26):2523-2533. doi: 10.1056/NEJMoa1612999. N Engl J Med. 2017. PMID: 28657871 Free article. Clinical Trial.
Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter. ...The lower boundary of the confidence interval for the difference in the decrease for tDCS versus escitalopram (difference, -2.3 points; 95% confidence interval [CI], -4.3 …
Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter. ...The lower boundary of the confidence i …
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Jacobsen PL, et al. J Sex Med. 2015 Oct;12(10):2036-48. doi: 10.1111/jsm.12980. Epub 2015 Aug 31. J Sex Med. 2015. PMID: 26331383 Clinical Trial.
METHODS: Participants treated with, and responding to, citalopram, paroxetine, or sertraline were randomized to switch to either vortioxetine (10/20 mg; n = 225) or escitalopram (10/20 mg; n = 222) for 8 weeks. ...RESULTS: Vortioxetine showed significantly greater i …
METHODS: Participants treated with, and responding to, citalopram, paroxetine, or sertraline were randomized to switch to either vort …
Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study.
Hsu CW, Tseng WT, Wang LJ, Yang YH, Kao HY, Lin PY. Hsu CW, et al. J Affect Disord. 2022 Jan 1;296:609-615. doi: 10.1016/j.jad.2021.10.009. Epub 2021 Oct 14. J Affect Disord. 2022. PMID: 34655698 Free article. Clinical Trial.
RESULTS: During the study period, a total of 207,946 elderly patients with depression received one of the following 11 antidepressants: sertraline, fluoxetine, paroxetine, escitalopram, citalopram, fluvoxamine, venlafaxine, duloxetine, moclobemide, mirtazapine, and …
RESULTS: During the study period, a total of 207,946 elderly patients with depression received one of the following 11 antidepressants: sert …
A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints.
Lavretsky H, Laird KT, Krause-Sorio B, Heimberg BF, Yeargin J, Grzenda A, Wu P, Thana-Udom K, Ercoli LM, Siddarth P. Lavretsky H, et al. Am J Geriatr Psychiatry. 2020 Feb;28(2):178-190. doi: 10.1016/j.jagp.2019.08.011. Epub 2019 Aug 22. Am J Geriatr Psychiatry. 2020. PMID: 31519517 Free PMC article. Clinical Trial.
METHODS: We conducted a 6-month double-blind placebo-controlled trial to assess the efficacy and tolerability of escitalopram + memantine (ESC/MEM) compared to escitalopram + placebo (ESC/PBO) for improving mood and cognitive functioning in depressed older adults wi …
METHODS: We conducted a 6-month double-blind placebo-controlled trial to assess the efficacy and tolerability of escitalopram + meman …
1,597 results